Joshua Whorton, MD
Gastroenterology · Norman, OKNPI 1346381969
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 1,109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. Among gastroenterology clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,109 payments — averaging $14.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Johnson & Johnson$1K
- Gilead$798
- QOL Medical, LLC$792
- plus $4K from 26 others
What the payments were for
- Consulting fees$150%
- Speaking & faculty fees$4003%
- Food & beverage$15,42597%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 245 | $3,615 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 216 | $2,847 |
| Takeda Pharmaceuticals U.S.A., Inc. | 182 | $2,258 |
| Johnson & Johnson(2 entities) | 84 | $1,185 |
| Gilead | 59 | $798 |
| QOL Medical, LLC | 23 | $792 |
| Bristol Myers Squibb | 55 | $703 |
| Ironwood Pharmaceuticals, Inc | 67 | $674 |
| Daiichi Sankyo Inc. | 31 | $437 |
| Pfizer | 18 | $314 |
| Ardelyx, Inc. | 16 | $277 |
| Sanofi | 17 | $271 |
| Medtronic | 4 | $201 |
| Regeneron Healthcare Solutions, Inc. | 9 | $173 |
| Nestle Healthcare Nutrition Inc. | 8 | $160 |
| Intercept Pharmaceuticals, Inc. | 10 | $159 |
| Ipsen Biopharmaceuticals, Inc | 11 | $146 |
| Madrigal Pharmaceuticals | 6 | $134 |
| Merck | 8 | $117 |
| Aimmune Therapeutics, Inc. | 6 | $107 |
| Braintree Laboratories, Inc. | 7 | $97 |
| Phathom Pharmaceuticals, Inc. | 5 | $83 |
| Olympus America Inc. | 4 | $58 |
| UCB, Inc. | 4 | $52 |
| Redhill Biopharma Inc. | 3 | $47 |
| Endo Pharmaceuticals Inc. | 3 | $39 |
| Ferring Pharmaceuticals Inc. | 2 | $34 |
| Organon | 2 | $28 |
| Biocon Biologics Inc | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Cook Medical LLC | 1 | $12 |
| Alfasigma USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,866 in reported general payments places this provider in the 90th percentile of 133 gastroenterology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 35 | $32,638 |
| Colestipol Hcl | 104 | $12,849 |
| MotegrityPrucalopride Succinate | 11 | $7,844 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 109 | $6,351 |
| Pantoprazole Sodium | 91 | $4,121 |
| Omeprazole | 196 | $3,850 |
| Ondansetron OdtOndansetron | 52 | $2,065 |
| Ursodiol | 16 | $1,729 |
| Esomeprazole Magnesium | 23 | $1,663 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 18 | $870 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 53 | $863 |
| Famotidine | 42 | $836 |
| LoperamideLoperamide Hcl | 15 | $803 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 48 | $749 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 45 | $728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $3,615 | $32,63835 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $2,258 | $7,84411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 133 gastroenterology providers in Oklahoma.
Other gastroenterology in Norman
- Andrew BlackNorman$21K
- Robert HolbrookNorman$12K
- Chintan ParikhNorman$11K
- Blair KirkpatrickNorman$11K
- Charles LackeyNorman$9K
- Philip BirdNorman$9K
- George SalemOklahoma City$1.2M
- Tauseef AliOklahoma City$536K
- Jeffrey HuntTulsa$155K
- Pooja SinghalOklahoma City$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.